{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T17:12:08Z","timestamp":1785604328282,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Health, Labor, and Welfare Sciences Research Grant from the Ministry of Health, Labor, and Welfare of Japan","award":["H30-Gantaisaku-ippan-009"],"award-info":[{"award-number":["H30-Gantaisaku-ippan-009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12185-021-03150-6","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:03:12Z","timestamp":1618596192000},"page":"246-251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of CHOP with THP-COP for peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective analysis using data from the population-based Osaka Cancer Registry"],"prefix":"10.1007","volume":"114","author":[{"given":"Shuhei","family":"Kida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Miyashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"issue":"20","key":"3150_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"11","key":"3150_CR2","first-page":"3909","volume":"89","author":"Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"Non-Hodgkin\u2019s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood. 1997;89(11):3909\u201318.","journal-title":"The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood."},{"issue":"10","key":"3150_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.7164\/antibiotics.32.1082","volume":"32","author":"H Umezawa","year":"1979","unstructured":"Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, et al. Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot. 1979;32(10):1082\u20134.","journal-title":"J Antibiot."},{"issue":"12","key":"3150_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.7164\/antibiotics.37.1697","volume":"37","author":"S Kunimoto","year":"1984","unstructured":"Kunimoto S, Miura K, Umezawa K, Xu C-Z, Masuda T, Takeuchi T, et al. Cellular uptake and efflux and cytostatic activity of 4\u2032-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. J Antibiot. 1984;37(12):1697\u2013702.","journal-title":"J Antibiot."},{"issue":"5","key":"3150_CR5","first-page":"688","volume":"29","author":"H Imura","year":"1988","unstructured":"Imura H, Ito N, Shirakawa S, Sobue R, Maruyama F, Kojima H, et al. THP-COP, BHAC-VMP alternating chemotherapy in patients with non-Hodgkin\u2019s lymphoma. Rinsho Ketsueki. 1988;29(5):688\u201393.","journal-title":"Rinsho Ketsueki"},{"issue":"2","key":"3150_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/hon.2262","volume":"35","author":"Y Shibata","year":"2017","unstructured":"Shibata Y, Hara T, Kasahara S, Yamada T, Sawada M, Mabuchi R, et al. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin. Hematol Oncol. 2017;35(2):163\u201371.","journal-title":"Hematol Oncol"},{"issue":"5","key":"3150_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1600-0609.1999.tb01137.x","volume":"63","author":"N Niitsu","year":"1999","unstructured":"Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin\u2019s lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol. 1999;63(5):337\u201344.","journal-title":"Eur J Haematol"},{"issue":"3","key":"3150_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1532\/IJH97.03147","volume":"81","author":"M Mori","year":"2005","unstructured":"Mori M, Kitamura K, Masuda M, Hotta T, Miyazaki T, Miura AB, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin\u2019s lymphoma. Int J Hematol. 2005;81(3):246\u201354.","journal-title":"Int J Hematol"},{"issue":"5","key":"3150_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1600-0609.2010.01411.x","volume":"84","author":"Y Takamatsu","year":"2010","unstructured":"Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, et al. THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia\/lymphoma: a multicenter phase II study. Eur J Haematol. 2010;84(5):391\u20137.","journal-title":"Eur J Haematol"},{"issue":"1","key":"3150_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/hon.2136","volume":"33","author":"N Tomita","year":"2015","unstructured":"Tomita N, Kodama F, Tsuyama N, Sakata S, Takeuchi K, Ishibashi D, et al. Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients. Hematol Oncol. 2015;33(1):9\u201314.","journal-title":"Hematol Oncol"},{"issue":"8","key":"3150_CR11","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.bbmt.2020.04.019","volume":"26","author":"S Fuji","year":"2020","unstructured":"Fuji S, Kida S, Morishima T, Nakata K, Miyashiro I, Ishikawa J. Clinical outcomes of patients with adult T Cell leukemia-lymphoma in a nonendemic metropolitan area: a retrospective analysis of the population-based Osaka cancer registry. Biol Blood Marrow Transplant. 2020;26(8):1433\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"3150_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2188\/jea.JE20170241","volume":"29","author":"T Morishima","year":"2019","unstructured":"Morishima T, Matsumoto Y, Koeda N, Shimada H, Maruhama T, Matsuki D, et al. Impact of comorbidities on survival in gastric, colorectal, and lung cancer patients. J Epidemiol. 2019;29(3):110\u20135.","journal-title":"J Epidemiol"},{"key":"3150_CR13","unstructured":"Shigemi D MT, Shibata A, Tabuchi T, Yasunaga H, Miyashiro I. Comparison of overall mortality between hysterectomy and concurrent chemoradiotherapy for the primary treatment of localized or regionally extended cervical cancer. Annals of clinical epidemiology. In press."},{"key":"3150_CR14","unstructured":"Morishima T SA, Nakata K, Miyashiro I. Geriatric assessment domains to predict overall survival in older cancer patients: an analysis of functional status, comorbidities, and nutritional status as prognostic factors. Cancer Medicine. In press."},{"issue":"15","key":"3150_CR15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2169\/internalmedicine.4308-19","volume":"59","author":"Y Miyamoto","year":"2020","unstructured":"Miyamoto Y, Ohbe H, Ishimaru M, Matsui H, Fushimi K, Yasunaga H. The effect of carbazochrome sodium sulfonate in patients with colonic diverticular bleeding: propensity score matching analyses using a Nationwide inpatient database. Inter Med. 2020;59(15):1789\u201394.","journal-title":"Inter Med"},{"issue":"14","key":"3150_CR16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med."},{"issue":"7","key":"3150_CR17","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474\u20139.","journal-title":"Blood"},{"issue":"9","key":"3150_CR18","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","volume":"111","author":"N Mourad","year":"2008","unstructured":"Mourad N, Mounier N, Bri\u00e8re J, Raffoux E, Delmer A, Feller A, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) trials. Blood. 2008;111(9):4463\u201370.","journal-title":"Blood"},{"issue":"3","key":"3150_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"3150_CR20","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood"},{"issue":"5","key":"3150_CR21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14740","volume":"178","author":"H Cederleuf","year":"2017","unstructured":"Cederleuf H, Bjerreg\u00e5rd Pedersen M, Jerkeman M, Relander T, d\u2019Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: a Nordic Lymphoma Group study. Br J Haematol. 2017;178(5):739\u201346.","journal-title":"Br J Haematol"},{"issue":"8","key":"3150_CR22","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","volume":"98","author":"A Janikova","year":"2019","unstructured":"Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019;98(8):1961\u201372.","journal-title":"Ann Hematol"},{"issue":"1","key":"3150_CR23","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1002\/acg2.6","volume":"1","author":"T Shichijo","year":"2018","unstructured":"Shichijo T. Hematopoietic stem cell transplantation for T-cell lymphoma. Adv Cell Gene Ther. 2018;1(1):e6.","journal-title":"Adv Cell Gene Ther"},{"issue":"25","key":"3150_CR24","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"10168","key":"3150_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-021-03150-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-021-03150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T10:16:28Z","timestamp":1626948988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-021-03150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3150"],"URL":"https:\/\/doi.org\/10.1007\/s12185-021-03150-6","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"assertion":[{"value":"2 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional review board of the Osaka International Cancer Institute in Osaka, Japan (No. 19088).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}